Manager, GRS, Advertising, Labeling, & Promotion
Blueprint Medicines | |
paid time off, 401(k)
| |
United States, Massachusetts, Cambridge | |
45 Sidney Street (Show on map) | |
Oct 24, 2025 | |
|
How will your role help us transform hope into reality? As GRS Manager of Advertising, Labeling, & Promotion, you will review and submit compliant advertising materials for our commercial portfolio. Responsibilities include ensuring content meets promotional regulations (US and Ex-US), completing FDA 2253 submissions, and adhering to FDA and company policies. What will you do?
What minimum qualifications do we require?
What additional qualifications will make you a stronger candidate?
Why Blueprint? At Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators - the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success. This is the place where the extraordinary becomes reality, and you could be part of it. Patients are waiting. Are you ready to make the leap? Compensation and Benefits The base salary hiring range for this position will be $125,000 -- $ 165,000.* Actual base salary offered for this position will be based on a number of job-related factors, including, but not limited to: experience (including skills and competencies), education, training and internal equity. This position is also eligible for the following:
*Based on reasonable estimate for this job at the time of posting; ranges are reviewed periodically and subject to change. To apply, just scroll down and click on the "Apply Now" link. Equal Employment Opportunity At Blueprint Medicines, we foster an environment of fair treatment and full participation for all of our employees as we navigate complex challenges in pursuing our mission to improve the lives of patients. We celebrate our unique differences and varied career and life experiences so that we can sustain our diverse culture and ensure everyone feels accepted. We are committed to non-discrimination, equal employment opportunity, as well as an inclusive recruitment process. We consider all qualified applicants based on merit and without regard to race, color, sex, gender identity, sexual orientation, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, or any other characteristic protected under applicable federal or state law. We will make reasonable accommodations, absent undue hardship, for qualified individuals with known disabilities. If you are an individual with a disability in need of an accommodation with the application or recruiting process, please reach out toTotalRewards@blueprintmedicines.com. We are also an E-Verify Employer. For more information, please see our EEO Policy Statement, the E-Verify Participation Poster, the Right to Work Poster, and/or the EEO Know Your Rights Poster. Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines, including bringing our medicine to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. | |
paid time off, 401(k)
Oct 24, 2025